Home > Boards > US OTC > Biotechs > Sangamo Biosciences Inc. (SGMO)

BioSciences logoSangamo BioSciences Inc. (NASDAQ:SGMO) was the recipient

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
ofthegreenes Member Profile
 
Followed By 15
Posts 1,370
Boards Moderated 1
Alias Born 11/30/16
160x600 placeholder
Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer Business Wire - 9/30/2019 4:15:00 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 9/30/2019 8:30:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/26/2019 6:16:05 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 8/30/2019 8:30:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 5:11:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 8/14/2019 5:05:41 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:45:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/7/2019 4:38:07 PM
Sangamo Therapeutics Reports Second Quarter 2019 Financial Results Business Wire - 8/7/2019 4:01:00 PM
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences Business Wire - 8/6/2019 4:05:00 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 8/6/2019 4:03:48 PM
Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel Business Wire - 7/31/2019 4:15:00 PM
Sangamo Therapeutics Announces Second Quarter 2019 Conference Call and Webcast Business Wire - 7/31/2019 4:05:00 PM
Sangamo Announces Nature Biotechnology Publication of New Strategies for Optimizing the Specificity of Gene Editing Nucleases Business Wire - 7/29/2019 11:00:00 AM
Sangamo et Pfizer annoncent des résultats de phase 1/2 mis à jour pour la thérapie génique expérimentale de l’hémoph... Business Wire - 7/8/2019 10:05:00 AM
Sangamo Therapeutics Up 17%; Unveiled Updated Study Data Dow Jones News - 7/8/2019 8:43:00 AM
Sangamo & Pfizer Announce Updated Phase 1/2 Results for SB-525 Investigational Hemophilia A Gene Therapy Showing Sustained In... Business Wire - 7/5/2019 11:15:00 PM
 Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease Allele-Selective Zinc Finger P... Business Wire - 7/1/2019 11:00:00 AM
Sangamo Announces Upcoming Presentation Of Investigational SB-525 Hemophilia A Gene Therapy Data At ISTH 2019 PR Newswire (US) - 6/21/2019 9:16:00 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/18/2019 5:03:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:03:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:14:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:10:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:09:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:08:23 PM
ofthegreenes   Thursday, 10/26/17 08:08:55 AM
Re: None
Post # of 340 
BioSciences logoSangamo BioSciences Inc. (NASDAQ:SGMO) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 7,636,100 shares, a decrease of 12.2% from the August 31st total of 8,693,947 shares. Currently, 11.1%

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist